FIELD: biotechnology.
SUBSTANCE: disclosed is a multimeric antibody which recognizes ganglioside OAcGD2 for the selective delivery of at least one anti-cancer agent having a molecular weight in range of 100 to 200,000 Da, into a cell expressing ganglioside OAcGD2. Said antibody is used in a composition and method for delivering an anti-cancer agent into a cell expressing ganglioside OAcGD2, in a method for increasing the effectiveness of treating cancer expressing ganglioside OAcGD2 using an anticancer agent, in methods for preventing and treating refractory or recurrent cancer in a patient.
EFFECT: invention provides a synergistic effect of a combined treatment with an antibody specifically targeting ganglioside OAcGD2, and anticancer agents on forms of cancer expressing ganglioside OAcGD2, which enables to reduce dosages and, consequently, toxic side effects from anticancer agents.
22 cl, 7 dwg, 6 tbl
| Title |
Year |
Author |
Number |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN |
2012 |
- Morisso Sebastyan Danel
- Teppa Zheraldin
- Zhak Yannik Loran Zhozef
- Rober Bruno Zhilber Mark
- De Martinoff Gi Lyuk Mishel
- Beshar David
|
RU2763298C2 |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES |
2018 |
- Guz, Elvire
- Garsiya, Stefani
|
RU2794170C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 |
2020 |
- Rontsitti, Dzhuzeppe
- Zhoz, Luiza
- Sharl, Severin
- Mingotstsi, Frederiko
|
RU2815545C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR |
2018 |
- Barret Jean-Marc
- Prost Jean-Francois
- Lahmar Mehdi
- Degove Stephane
- Bougherara Houcine
- Donnadieu Emmanuel
|
RU2805232C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION |
2017 |
- Guz, Elvire
- Garsiya, Stefani
|
RU2751483C2 |
| IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS |
2020 |
- Go, Yujgan
- Tan, Li
- Se, Yuj-Tsin
|
RU2825306C1 |
| COMPOSITION FOR TREATING CANCER, COMBINING ANTI-CD26 ANTIBODY AND OTHER ANTI-CANCER AGENT |
2016 |
- Yamada Taketo
- Khayasi Mutsumi
- Yamada Kokhdzi
- Morimoto Tikao
- Okamoto Tosikhiro
- Kaneko Yutaro
|
RU2742953C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE |
2018 |
- De, Arnab
- Narasimkhan, Chakravarti Nachu
|
RU2820576C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES |
2014 |
- Morsey, Mohamad
- Zhang, Yuanzheng
- Tarpey, Ian
|
RU2815059C2 |
| PEPTIDES AND THEIR USE IN TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT p53 |
2017 |
- Rotter, Varda
- Oren, Moshe
- Tal, Perry
- Eizenberger, Shay
- Ben-Shimon, Avi
|
RU2762089C2 |
